Matuzumab

Jump to: navigation, search
Matuzumab
Monoclonal antibody
Type?
SourceTemplate:Infobox drug/mab source
TargetEGFR
Identifiers
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).

WikiDoc Resources for Matuzumab

Articles

Most recent articles on Matuzumab

Most cited articles on Matuzumab

Review articles on Matuzumab

Articles on Matuzumab in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Matuzumab

Images of Matuzumab

Photos of Matuzumab

Podcasts & MP3s on Matuzumab

Videos on Matuzumab

Evidence Based Medicine

Cochrane Collaboration on Matuzumab

Bandolier on Matuzumab

TRIP on Matuzumab

Clinical Trials

Ongoing Trials on Matuzumab at Clinical Trials.gov

Trial results on Matuzumab

Clinical Trials on Matuzumab at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Matuzumab

NICE Guidance on Matuzumab

NHS PRODIGY Guidance

FDA on Matuzumab

CDC on Matuzumab

Books

Books on Matuzumab

News

Matuzumab in the news

Be alerted to news on Matuzumab

News trends on Matuzumab

Commentary

Blogs on Matuzumab

Definitions

Definitions of Matuzumab

Patient Resources / Community

Patient resources on Matuzumab

Discussion groups on Matuzumab

Patient Handouts on Matuzumab

Directions to Hospitals Treating Matuzumab

Risk calculators and risk factors for Matuzumab

Healthcare Provider Resources

Symptoms of Matuzumab

Causes & Risk Factors for Matuzumab

Diagnostic studies for Matuzumab

Treatment of Matuzumab

Continuing Medical Education (CME)

CME Programs on Matuzumab

International

Matuzumab en Espanol

Matuzumab en Francais

Business

Matuzumab in the Marketplace

Patents on Matuzumab

Experimental / Informatics

List of terms related to Matuzumab


Overview

Matuzumab (formerly EMD 72000) is a humanized monoclonal antibody for the treatment of cancer. It binds to EGFR (epithelial growth factor receptor) with high affinity.

Developed by Merck Serono in cooperation with Takeda Pharmaceutical, it is currently undergoing phase II clinical trials for the treatment of colorectal, lung and stomach cancer. On August 29, 2007, Merck Serono announced that the preliminary results of the colorectal cancer study were less than promising, and that further trials for treating this type of cancer may be abandoned. The results of the lung and stomach cancer studies are expected in 2008.[1]

Footnotes

  1. Krebsmedikament floppt. n-tv, August 29, 2007. [Article in Gemran]. Retrieved 2007-AUG-27.

External link

de:Matuzumab



Linked-in.jpg